In:
PARIPEX INDIAN JOURNAL OF RESEARCH, World Wide Journals
Abstract:
Introduction: Community-acquired acute lower respiratory tract infection (LRTI) incorporates a spectrum of diseases
from acute bronchitis, acute exacerbation of chronic obstructive pulmonary disease (COPD) and pneumonia. It is the most common cause for consulting general practice and OPD. This study was undertaken to compare older and newer
antimicrobials in terms of clinical efficacy, tolerability and cost for the initial treatment for OPD management of LRTI in a government medical college setup. This randomized, prospective study was conducted in theMaterial And Methods:
Medicine OPD of a government medical college, over a period of one year.Patients of either sex, aged between 16-60 yrs satisfying following definitions of acute bronchitis (with secondary bacterial infection), acute exacerbation of COPD and
community acquired pneumonia were selected for the study. Patients were randomly assigned to one of the following treatment groups:
Ÿ Group I- Amoxicillin 500 mg three times a day for 7 days. Ÿ Group II - Erythromycin 500mg four times a day for 7 days
Ÿ Group III - Cefadroxil 500mg two times a day for 7 days Ÿ Group IV-Gatifloxacin 400mg once a day for 7 day
Efficacy and safety of all antimicrobials were assessed and compared Results: Satisfactory clinical outcome as cure and improvement was obtained in 48 % and 36% in amoxicillin, 52% and
33% in erythromycin 49% and 38% in cefadroxil, 64% and 27% in gatifloxacin group respectively. Unsatisfactory clinical outcome as failure was recorded in 16%, 15%, 13% and 9% of amoxicillin, erythromycin, cefadroxil and gatifloxacin
groups respectively. All the four drugs were equally effective with more than 80% efficacy in treatment ofConclusions: LRTI. The treatment groups did not differ in incidence of adverse events. All the adverse effects were mild and did not
require cessation of therapy.
Type of Medium:
Online Resource
DOI:
10.36106/paripex/2500364
Language:
English
Publisher:
World Wide Journals
Publication Date:
2022
